{"filing":{"accession_number":"0001828316-26-000035","cik":"0001828316","ticker":"PHAR","company_name":"Pharming Group N.V.","form":"6-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"pharmingannouncescommercia.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828316/000182831626000035/pharmingannouncescommercia.htm"},"events":[{"id":27418,"run_id":24989,"accession_number":"0001828316-26-000035","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4 and older, following inclusion on the Japan National Health Insurance drug price list. This represents a material operational and commercial milestone—the first market where Joenja is available for children aged 4–11—that would affect a reasonable investor's assessment of Pharming's commercial progress and market expansion. While not a discrete M\u0026A, financing, or governance event, it is a significant product commercialization milestone in a rare-disease therapeutic area.","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-08-13","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":28950,"accession_number":"0001828316-26-000035","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4 and older, following inclusion on the Japan National Health Insurance drug price list. This represents a material operational and commercial milestone—the first market where Joenja is available for children aged 4–11—that would affect a reasonable investor's assessment of Pharming's commercial progress and market expansion. While not a discrete M\u0026A, financing, or governance event, it is a significant product commercialization milestone in a rare-disease therapeutic area.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:12:44.584674+00:00","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-08-13"}]}